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normal parenchyma they remodel the composition and ultrastructure of the
surrounding extracellular matrix (ECM), suggesting that the native (i.e., “normal”)
microenvironment is not ideal for their survival and proliferation. Recent reports
describe suppressive and/or lethal effects of mammalian ECM hydrogels derived
from normal (nonneoplastic) sources upon various cancer types. ECM-based
bioscaffolds placed at sites of neoplastic tissue resection in humans have never
been reported to facilitate cancer recurrence. The objective of the present
research is to evaluate mammalian ECM as a novel approach to glioma therapy.
METHODS/STUDY POPULATION: ECM hydrogels from porcine dermis, small
intestine, and urinary bladder were produced as described previously. Primary
glioma cells were graciously supplied by Drs. Nduka Amankulor and Johnathan
Engh, and U-87 MG were ordered through ATCC. Cells were plated onto tissue
culture plastic at ~ 60% confluence and allowed to attach for 24 hours before
treatment. The saline-soluble fraction (SSF) of ECM was obtained by mixing
lyophilized, comminuted ECM with 0.9% saline for 24 hours then filtering the
resulting mixture through a 10 kDa molecular weight cutoff column. All assays
and kits were followed according to the manufacturer’s instructions. Cell viability
was measured via MTT assay (Vybrant® MTT Cell Proliferation Assay, Invitrogen)
and by live/dead staining (LIVE/DEAD® Cell Imaging Kit, Invitrogen). Time lapse
videos were created by taking images every 20 minutes for 18 hours (phase-
contrast) or every 10 minutes for 12 hours (darkfield). NucView reagent was
ordered from Biotium. Temozolomide was ordered through Abmole. All in vivo
work was conducted according to protocols approved by the University of
Pittsburgh’s IACUC office. RESULTS/ANTICIPATED RESULTS: ECM hydrogels
derived from porcine dermis, small intestine, or urinary bladder all decreased the
viability of primary glioma cells in vitro, with urinary bladder extracellular matrix
(UBM) having the most dramatic effects. The SSF of UBM (UBM-SSF), devoid of
the fibrillar, macromolecular components of ECM, was sufficient to recapitulate
this detrimental effect upon neoplastic cells in vitro and was used for the
remainder of the experiments described herein. In a cell viability assay normalized
to the media treatment, non-neoplastic CHME5 and N1E-115 cells scored 103%
and 114% after 48 hours when treated with UBM-SSF and 2 primary high-grade
glioma cell types scored 17% and 30.5% with UBM-SSF (n= 2). Phase-contrast
time-lapse video showed CHME5 and HFF thriving in the presence of UBM-SSF
for 18 hours while most primary glioma cells shriveled and died within this time.
Darkfield time-lapse video of wells containing Nucview dye, fluorescent upon
cleavage by active caspase-3, confirmed that within 12 hours most primary
glioma cells underwent apoptosis while CHME5 and HFF did not. In culture
with primary astrocytes, high grade primary glioma cells, and U-87 MG glioma
cells for 24 hours, UBM-SSF was found to significantly increase the population
of primary astrocytes compared with media (p< 0.05) while decreasing the 2
glioma cell types to approximately one-third as many cells as the media
control (p< 0.0001). A dose-response of temozolomide from 0 to 10,000 μM
showed that when treating 2 non-neoplastic cell types (CHME5 and HFF) and
2 types of primary glioma cell there was no difference in survivability at any
concentration. Contrasted to this, a dose-response of UBM-SSF from 350 to
7000 μg/mL showed that the non-neoplastic cells survived significantly better
than the glioma cells at concentrations of 875 μg/mL and upward (p< 0.05). In
preliminary animal experiments, large primary glioma tumors in the flanks of
athymic nude mice were resected and replaced with either UBM SSF or
Matrigel (an ECM product of neoplastic cell origin). After 7 days the resection
sites with UBM-SSF had little tumor regrowth if any compared with the
dramatic recurrence seen in the Matrigel injection sites (n= 2). In a separate
survival study comparing PBS to UBM-SSF injections in the flank-resection
model, all animals given PBS had to be sacrificed at 9, 11, and 11 days (n= 3)
whereas animals given UBM-SSF were sacrificed at 15, 24, and 39 days (n= 3),
indicating a moderate increase in survival due to the UBM-SSF. DISCUSSION/
SIGNIFICANCE OF IMPACT: Since the introduction of the pan-cytotoxic
chemotherapeutic agent TMZ in 2005, the standard of care for patients with
glioblastoma multiforme has not improved. These findings indicate that non-
neoplastic ECM contains potent bioactive regulators capable of abrogating
malignancy. Our in vitro data suggest these molecules appear to have no
deleterious effect on non-neoplastic cells while specifically inducing apoptosis
in glioma cells. Our in vivo data suggest that these molecules may be useful in
delaying glioma recurrence, thus resulting in extended lifespan. Delivering
soluble fractions of ECM to a tumor site may represent a novel approach to
glioma therapy, sidestepping traditional cytotoxic therapies in favor of utilizing
putative endogenous anti-tumor pathways.
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Feasibility, acceptability, and appropriateness of the
menstrual cup for short-term non-surgical
management of vesicovaginal fistula (VVF) among
potential users and stakeholders
Nessa E. Ryan
H+H Clinical and Translational Science Institute, NYU
OBJECTIVES/SPECIFIC AIMS: To examine how women with OF in Ghana
develop strategies for coping in the absence of access to successful surgical
repair. To assess the feasibility, acceptability, and appropriateness of an
innovation to support coping among women with OF seeking care in a health
facility in Ghana. To examine the perceived facilitators and barriers to
implementation among additional OF stakeholders regarding the innovation.
METHODS/STUDY POPULATION: This study uses a sequential exploratory
mixed methods design. The population of study is women in Ghana living with
obstetric fistula, as well as additional fistula stakeholders (programmers, policy
makers, community leaders). To get an understanding of usual leakage, women
carried out at baseline a pad test, where they wore a sanitary pad for 2 hours
and leaked freely.We subtracted the dry pad weight from the wet pad weight to
estimate urine leakage in mL. Then women inserted the cup for 2 hours and
again wore a pad and urine leakage was estimated. Acceptability among women
with vesicovaginal fistula was measured by questionnaire. Acceptability among
additional stakeholders was examined by semistructured interview. Appro-
priateness was assessed among the user, additional stakeholders, and
organizational setting. RESULTS/ANTICIPATED RESULTS: We observed a
61% mean reduction in leakage with the cup which was also perceived by cup
users as a reduction in wetness. Notably, one participant who had 4 previous
surgical attempts, experienced a 78% reduction in leakage. No adverse events
attributable to use of the cup were observed, unlike some of the strategies
women currently use to manage leakage. Acceptability was high as most women
could easily insert, remove, and wear the cup over the 2-hour period and fistula
stakeholders indicated the innovation content and complexity were acceptable.
In community interviews, women shared various coping and self-care strategies
to manage their leaking, other related impairments, and stigma. Women using
the cup in the health facility expressed that it was useful. Additional
stakeholders found the cup a low-cost, low-tech solution to supplement
existing programs.Within the stakeholder interviews we heard that the cultural
norms and existing activities of the potential implementation partners align with
the innovation approach. Stakeholders revealed various implementation
facilitators and barriers. The facilitators to implementation reported in the
interviews were related to the intervention and organization characteristics in
particular. Stakeholders perceived a relative advantage to self-management.
Stakeholders had concerns regarding whether women would find the insertable
device acceptable and appropriate—questioning whether potential users would
have access to water, soap, and safe space to empty cup. DISCUSSION/
SIGNIFICANCE OF IMPACT: The innovation is efficacious, acceptable, adds to
current coping strategies, and fits within existing fistula programs. Stakeholders
pre-implementation perceptions highlight the importance of partnerships and
the need for an evidence base related to effectiveness, acceptability, and cost.
Challenges to address include access to resources within these contexts (water,
soap, and safe space) and development appropriate counseling message.
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OBJECTIVES/SPECIFIC AIMS: Objectives and goals of this study will be to: (1)
compare fecal microbiota and fecal organic acids in irritable bowel syndrome (IBS)
patients and controls and (2) investigate the association between colonic transit and
fecal microbiota in IBS patients and controls. METHODS/STUDY POPULATION:
We propose an investigation of fecal organic acids, colonic transit and fecal
microbiota in 36 IBS patients and 18 healthy controls. The target population will be
adults ages 18–65 years meeting Rome IV criteria for IBS (both diarrhea- and
constipation-predominant, IBS-D and IBS-C) and asymptomatic controls. Exclusion
criteria are: (a) history of microscopic colitis, inflammatory bowel disease, celiac
disease, visceral cancer, chronic infectious disease, immunodeficiency, uncontrolled
thyroid disease, liver disease, or elevated AST/ALT>2.0× the upper limit of
normal, (b) prior radiation therapy of the abdomen or abdominal surgeries with the
exception of appendectomy or cholecystectomy>6months before study initiation,
(c) ingestion of prescription, over the counter, or herbal medications affecting
gastrointestinal transit or study interpretation within 6 months of study initiation
for controls or within 2 days before study initiation for IBS patients, (d) pregnant
females, (e) antibiotic usage within 3months before study participation, (f) prebiotic
or probiotic usage within the 2 weeks before study initiation, (g) tobacco users.
Primary outcomes will be fecal bile acid excretion and profile, short-chain fatty acid
excretion and profile, colonic transit, and fecal microbiota. Secondary outcomes
will be stool characteristics based on responses to validated bowel diaries. Stool
samples will be collected from participants during the last 2 days of a 4-day 100 g fat
diet and split into 3 samples for fecal microbiota, SCFA, and bile acid analysis and
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frozen. Frozen aliquots will be shipped to the Metabolite Profiling Facility at Purdue
University and the Mayo Clinic Department of Laboratory Medicine and Pathology
for SCFA and bile acid measurements, respectively. Analysis of fecal microbiota will
be performed in the research laboratory of Dr David Nelson in collaboration with
bioinformatics expertise affiliated with the Nelson lab. Colonic transit time will be
measured with the previously validated method using radio-opaque markers.
Generalized linear models will be used as the analysis framework for comparing
study endpoints among groups. RESULTS/ANTICIPATED RESULTS: This study
seeks to examine the innovative concept that specific microbial signatures are
associated with increased fecal excretion of organic acids to provide unique insights
on a potential mechanistic link between altered intraluminal organic acids and fecal
microbiota. DISCUSSION/SIGNIFICANCE OF IMPACT: Results may lead to
development of targets for novel therapies and diagnostic biomarkers for IBS,
emphasizing the role of the fecal metabolome.
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OBJECTIVES/SPECIFIC AIMS: This abstract describes a recently-funded 2 year
study that aims to: (1) explore the community advisors’ perspectives of the safe
sleep intervention’s acceptability, feasibility, and adaptability using focus
groups and key informant interviews. (2) Adapt the selected safe sleep
interventions (SSI) and identify promising implementation strategies to
support it through an evidence-based quality improvement process with a
multistakeholder group. METHODS/STUDY POPULATION: Background
sudden unexpected infant death (SUID) is the leading cause of post-neonatal
infant death in the United States. Sudden infant death syndrome (SIDS),
accidental suffocation and strangulation in bed account for over 50% of SUID,
leading to recommendations for supine sleep position and safer sleep
environments for infants. However, despite significant reductions in SIDS
after “back to sleep” and “safe to sleep” campaigns, significant racial and
urban-rural disparities persist. In 2015, the rural-urban crude death rate ratio
was 4:1 and Black infants are twice as likely to die from SUID as White infants.
Adherence to safe sleep recommendations is highly variable and a number of
hospital and community-based interventions have been suggested to improve
knowledge and change parent behavior. Hospital programs to promote safe
sleep education and policies may serve to educate families about safe sleep,
but may not be uniformly available in rural and underserved areas. The AAP
evidence-based safe sleep guidelines have demonstrated reductions in SIDS
and SUID when child caregivers adhere to them. Community-based SSI,
including safety baby showers, promote safe sleep practices, but barriers may
exist for participation, especially in rural areas. Partnering with community
groups serving a high risk area, we will explore the barriers and facilitators to
more widespread safety baby shower (SBS) delivery/adoption in rural
underserved communities (RUC). Observation of the evidence-based SBS as
it is currently delivered, focus groups and key informant interviews will be
conducted with program leaders and participants. Based on this knowledge
and using an evidence-based development process, we will adapt the SBS and
identify implementation strategies to support its uptake in RUC. RESULTS/
ANTICIPATED RESULTS: We expect to develop a modified safe sleep
intervention that reaches more expectant and new mothers is more efficient
at delivering safe sleep guidelines to rural community members and can be
more readily adopted and implemented by RUC. Supporting implementation
strategies will be identified during the formative evaluation. DISCUSSION/
SIGNIFICANCE OF IMPACT: Developing a safe sleep intervention adapted
for the local context through a collective decision-making process between
intervention experts and local community advisors will potentially improve
safe sleep guideline delivery and adherence in RUC. The next study will pilot
test the effectiveness of the adapted safe sleep intervention with identified
supporting implementation strategies.
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Functional characterization of mutant BRCA1
John Barrows and David Long
University of South Carolina
OBJECTIVES/SPECIFIC AIMS: The objective of this work is to determine the
mechanistic consequences of BRCA1 mutants in inter-strand crosslink (ICL)
repair. METHODS/STUDY POPULATION: Our lab uses Xenopus egg
extracts to study ICL repair. These extracts can be depleted of endogenous
BRCA1 by immunoprecipitation. The goal of this work is to rescue
endogenous depletion with in vitro translated, wild type BRCA1. Once
achieved, we can supplement the depleted extract with BRCA1 mutants to
access their function in ICL repair. RESULTS/ANTICIPATED RESULTS: We
hypothesize that the BRCT and RING domain mutations will abrogate ICL
repair, while mutations in the coiled coil region will not affect repair.
DISCUSSION/SIGNIFICANCE OF IMPACT: These findings will have an
immense impact on the understanding of BRCA1 domains. Importantly these
results will spur personalized therapy of BRCA1 mutants by showing which
domains are sensitive to cross-linking agents.
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Genital microbiomes of women with recurrent
bacterial vaginosis and their regular male sexual
partner
Christina A. Muzny, William J. Van Der Pol, Elliot J. Lefkowitz, Arin-
dam Ghosh, Mei Li, David Redden, Xiangqin Cui and Jane Schwebke
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OBJECTIVES/SPECIFIC AIMS: Epidemiologic data suggest that BV is sexually
transmitted with male partners colonized or infected with the responsible
organism(s). The objective of this study was to compare the genital microbiota
of women with recurrent BV and their regular male sexual partner using 16S
rRNA gene sequencing and quantitative PCR targeting BV-candidate bacteria
(Gardnerella vaginalis, Atopobium vaginae, BVAB1-3, Sneathia, Leptotrichia, and
Megasphaera type I). METHODS/STUDY POPULATION: Women with
recurrent BV (≥3 prior episodes, including a current episode) and their regular
male partner participating in a BV treatment trial and providing genital
specimens (women: vaginal; men: urethral, coronal sulcus, urine) at enrollment
were included. Male specimens for each participant were pooled. 250 bp 16S
rRNA V4 region PCR amplicons were sequenced and analyzed using the QIIME
pipeline. Taxonomy was assigned using the RDP Classifier against a modified
Greengenes database with additional vaginal taxonomies added. An average
relative abundance cutoff of 0.5% was used for analysis. qPCR was also
performed for specific BV-candidate bacteria. Spearman correlation coefficients
were used to investigate associations between all genital bacteria in addition to
BV-candidate bacteria between partnerships. To determine positive associa-
tions between partnerships, theWilcoxon signed-rank test was used. RESULTS/
ANTICIPATED RESULTS: In total, 45 partnerships were included. Mean
partnership age was 31.3 (SD= 7.9), 91.1% partnerships were African-
American. The majority of partnerships (70.0%) reported condomless sex
during the past 3 months. Regarding 16S data, 37 genital bacteria had an average
relative abundance of ≥0.5%. The average Spearman correlation across all 45
partnerships was 0.28 (SD= 0.27) (median= 0.27, minimum= − 0.21, max-
imum= 0.84). Overall, a positive association of all genital bacteria existed across
the partnerships (p< 0.0001). However, regarding specific BV-candidate
bacteria, Spearman correlation tests for G. vaginalis, A. vaginae, Prevotella bivia,
Megasphaera type I, BVAB1, and BVAB2 were nonsignificant. In contrast,
Sneathia spp. were positively correlated between partnerships (r= 0.37,
p= 0.01). With regards to qPCR results, RNA Cq analyses provided significant
evidence for a linear association between male and females for only A. vaginae
(r= 0.52, p= 0.006). DISCUSSION/SIGNIFICANCE OF IMPACT: In mono-
gamous heterosexual couples in which the female has BV, the vaginal microbiota
of women and the penile/urine microbiota of men were significantly correlated,
particularly with regards to Sneathia spp. and A. vaginae, supporting the
hypothesis that BV-associated bacteria are exchanged during sex.
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High concentrations of CXCL12 decrease pancreatic
adenocarcinoma growth
Emily Vonderhaar, Michael Dwinell, Ishan R. Roy, Donna M. McAllis-
ter and Michael B. Dwinell
Medical College of Wisconsin
OBJECTIVES/SPECIFIC AIMS: We hypothesized that CXCL12, as a biased
dimer variant or secreted at dimer-dominant concentrations, would influence
PDAC growth and progression. METHODS/STUDY POPULATION: PDAC
cells were genetically manipulated to express dimer-promoting levels of
CXCL12. These cells were studied in vitro or orthotopically implanted into the
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